SG166817A1 - Platelet aggregation inhibitor composition - Google Patents

Platelet aggregation inhibitor composition

Info

Publication number: SG166817A1
Authority: SG; Singapore
Prior art keywords: amino acid; acid sequence; polypeptide; platelet aggregation; inhibitory activity
Prior art date: 2005-11-04

Application number

SG201008077-8A

Other languages

English (en)

Inventor

Shigeto Yoshida

Toshiki Sudo

Original Assignee

Educational Foundation Jichi M

Otsuka Pharma Co Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-11-04

Filing date

2006-11-02

Publication date

2010-12-29

2006-11-02 Application filed by Educational Foundation Jichi M, Otsuka Pharma Co Ltd filed Critical Educational Foundation Jichi M

2010-12-29 Publication of SG166817A1 publication Critical patent/SG166817A1/en

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
- C07K14/43563—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5082—Supracellular entities, e.g. tissue, organisms
- G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Zoology (AREA)
Immunology (AREA)
Biomedical Technology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Hematology (AREA)
Genetics & Genomics (AREA)
Urology & Nephrology (AREA)
Biochemistry (AREA)
Biotechnology (AREA)
Gastroenterology & Hepatology (AREA)
Cardiology (AREA)
Cell Biology (AREA)
Microbiology (AREA)
Tropical Medicine & Parasitology (AREA)
Physics & Mathematics (AREA)
Toxicology (AREA)
Wood Science & Technology (AREA)
Heart & Thoracic Surgery (AREA)
Biophysics (AREA)
General Engineering & Computer Science (AREA)
Analytical Chemistry (AREA)
Epidemiology (AREA)
Diabetes (AREA)
Insects & Arthropods (AREA)

SG201008077-8A 2005-11-04 2006-11-02 Platelet aggregation inhibitor composition SG166817A1 (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
JP2005320817		2005-11-04

Publications (1)

Publication Number	Publication Date
SG166817A1 true SG166817A1 (en)	2010-12-29

Family

ID=38005983

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SG201008077-8A SG166817A1 (en)	2005-11-04	2006-11-02	Platelet aggregation inhibitor composition

Country Status (18)

Country	Link
US (2)	US8034763B2 (es)
EP (2)	EP2077328B1 (es)
JP (1)	JP4954204B2 (es)
KR (1)	KR101311570B1 (es)
CN (2)	CN102911264B (es)
AR (1)	AR057858A1 (es)
AU (1)	AU2006309543B2 (es)
BR (1)	BRPI0618194A2 (es)
CA (1)	CA2625106C (es)
ES (2)	ES2547380T3 (es)
IL (2)	IL188986A0 (es)
MY (1)	MY148135A (es)
PH (1)	PH12013502021B1 (es)
RU (2)	RU2434941C2 (es)
SG (1)	SG166817A1 (es)
TW (1)	TWI391143B (es)
WO (1)	WO2007052841A1 (es)
ZA (1)	ZA200801161B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN108503689B (zh) *	2017-07-10	2019-12-31	昆明医科大学第一附属医院	一种抗血小板聚集的多肽km6
CN108503692B (zh) *	2017-07-10	2019-12-31	昆明医科大学第一附属医院	一种促血小板聚集的多肽pep1
CN110339344B (zh) *	2019-08-07	2022-12-30	上海交通大学医学院附属仁济医院	核受体Rev-erbα在制备抗血小板药物中的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ATE210679T1 (de) *	1993-07-01	2001-12-15	Merck Patent Gmbh	Ein inhibitor der collagenstimulierten plättchenaggregation
CA2199719A1 (en) *	1994-09-12	1996-03-21	Christiane Noeske-Jungblut	Process for manufacture of a modified collagen-induced platelet aggregation inhibitor pallidipin
RU2192857C1 (ru) *	2001-04-24	2002-11-20	Институт органической химии им. Н.Д. Зелинского РАН	Ингибитор агрегации тромбоцитов, обладающий антиметастатическим действием
JP3648548B2 (ja) *	2001-10-15	2005-05-18	国立大学法人三重大学	血液凝固阻害活性を有するハマダラカ由来のＡｓ−１蛋白質
JP3837519B2 (ja)	2002-10-02	2006-10-25	国立大学法人三重大学	血小板凝集阻害活性を有するブラジルサシガメ由来のＴｉ−３蛋白質
JP3837518B2 (ja)	2002-10-02	2006-10-25	国立大学法人三重大学	血小板凝集阻害活性を有するブラジルサシガメ由来のＴｉ−４蛋白質

2006
- 2006-10-26 TW TW95139546A patent/TWI391143B/zh not_active IP Right Cessation
- 2006-11-02 SG SG201008077-8A patent/SG166817A1/en unknown
- 2006-11-02 CN CN201210390650.2A patent/CN102911264B/zh not_active Expired - Fee Related
- 2006-11-02 RU RU2008122338/10A patent/RU2434941C2/ru not_active IP Right Cessation
- 2006-11-02 EP EP09153422.2A patent/EP2077328B1/en not_active Not-in-force
- 2006-11-02 US US12/065,701 patent/US8034763B2/en not_active Expired - Fee Related
- 2006-11-02 MY MYPI20080355 patent/MY148135A/en unknown
- 2006-11-02 AU AU2006309543A patent/AU2006309543B2/en not_active Ceased
- 2006-11-02 ES ES06832470.6T patent/ES2547380T3/es active Active
- 2006-11-02 BR BRPI0618194-5A patent/BRPI0618194A2/pt not_active IP Right Cessation
- 2006-11-02 ES ES09153422.2T patent/ES2547404T3/es active Active
- 2006-11-02 JP JP2008519765A patent/JP4954204B2/ja not_active Expired - Fee Related
- 2006-11-02 RU RU2011120138/10A patent/RU2557296C2/ru not_active IP Right Cessation
- 2006-11-02 WO PCT/JP2006/322417 patent/WO2007052841A1/en not_active Ceased
- 2006-11-02 KR KR1020087013445A patent/KR101311570B1/ko not_active Expired - Fee Related
- 2006-11-02 CN CN2006800352979A patent/CN101273128B/zh not_active Expired - Fee Related
- 2006-11-02 ZA ZA200801161A patent/ZA200801161B/xx unknown
- 2006-11-02 CA CA2625106A patent/CA2625106C/en not_active Expired - Fee Related
- 2006-11-02 EP EP06832470.6A patent/EP1943337B1/en not_active Not-in-force
- 2006-11-03 AR ARP060104826A patent/AR057858A1/es unknown
2008
- 2008-01-24 IL IL188986A patent/IL188986A0/en unknown
2011
- 2011-08-22 US US13/215,004 patent/US8309512B2/en not_active Expired - Fee Related
2013
- 2013-09-27 PH PH12013502021A patent/PH12013502021B1/en unknown
- 2013-10-21 IL IL228986A patent/IL228986A0/en unknown

Also Published As

Publication number	Publication date
CA2625106A1 (en)	2007-05-10
PH12013502021A1 (en)	2015-12-14
TW200735887A (en)	2007-10-01
IL228986A0 (en)	2013-12-31
ES2547404T3 (es)	2015-10-06
AU2006309543B2 (en)	2012-01-19
AU2006309543A1 (en)	2007-05-10
US20100004164A1 (en)	2010-01-07
RU2011120138A (ru)	2012-11-27
ZA200801161B (en)	2009-08-26
JP2009514785A (ja)	2009-04-09
CN101273128A (zh)	2008-09-24
ES2547380T3 (es)	2015-10-05
HK1120074A1 (en)	2009-03-20
US8309512B2 (en)	2012-11-13
KR101311570B1 (ko)	2013-09-26
EP1943337A4 (en)	2008-12-03
JP4954204B2 (ja)	2012-06-13
PH12013502021B1 (en)	2019-02-01
BRPI0618194A2 (pt)	2011-08-23
CN102911264B (zh)	2014-03-19
CA2625106C (en)	2016-08-02
EP2077328A1 (en)	2009-07-08
CN102911264A (zh)	2013-02-06
US8034763B2 (en)	2011-10-11
KR20080105024A (ko)	2008-12-03
RU2008122338A (ru)	2009-12-10
IL188986A0 (en)	2008-08-07
EP2077328B1 (en)	2015-07-15
CN101273128B (zh)	2012-11-21
EP1943337B1 (en)	2015-07-15
WO2007052841A1 (en)	2007-05-10
RU2434941C2 (ru)	2011-11-27
EP1943337A1 (en)	2008-07-16
AR057858A1 (es)	2007-12-19
RU2557296C2 (ru)	2015-07-20
US20120004186A1 (en)	2012-01-05
TWI391143B (zh)	2013-04-01
MY148135A (en)	2013-02-28

Publication	Publication Date	Title
SG178797A1 (en)	2012-03-29	Oligosaccharide chain added glp-1 peptide
NZ600690A (en)	2014-03-28	Fkbp-l and uses thereof
HRP20090245T1 (en)	2009-07-31	Pyy agonists and uses thereof
EP2455462A3 (en)	2013-05-29	Lipase variants for pharmaceutical use
IS2714B (is)	2011-01-15	Uppsöfnun í frumu á phosphomate hliðstæðum á HIV próteasa hindrandi efnasamböndum
MY138708A (en)	2009-07-31	Biaryloxymethylarenecarboxylic acids
WO2003079972A3 (en)	2004-03-18	Active agent delivery systems and methods for protecting and administering active agents
WO2007002465A3 (en)	2007-10-04	Stabilizing alkylglycoside compositions and methods thereof
UA100127C2 (ru)	2012-11-26	Пептид cdh3 и лекарственное средство, содержащее его
WO2007097903A3 (en)	2008-05-22	Hiv fusion inhibitor peptides with improved biological properties
NZ586430A (en)	2012-09-28	Mutant forms of streptolysin o (slo)
MX2008009493A (es)	2008-10-03	Peptido novedoso y uso del mismo.
TW200633992A (en)	2006-10-01	Biaryloxymethylarenecarboxylic acids
NZ601142A (en)	2013-11-29	Composition for improving brain function and method for improving brain function
WO2006057003A3 (en)	2007-03-01	Induction of neurogenesis and stem cell therapy in combination with copolymer 1
IL175319A0 (en)	2006-09-05	Novel phosphate-binding protein, pharmaceutical compositions containing same and use thereof
PH12013502021A1 (en)	2015-12-14	Platelet aggregation inhibitor composition
ZA200901342B (en)	2010-11-24	Cytokine derivatives
CA2549185A1 (en)	2005-07-07	Peptide inhibiting angiotensin converting enzyme
NZ589365A (en)	2013-06-28	Peptidyl diacylglycerides
AU2007350619A8 (en)	2011-09-22	A purified recombinant batroxobin with high specific activity
WO2008066729A3 (en)	2008-09-25	Boronic acid containing compositions
WO2010079314A3 (en)	2010-09-10	Polypeptides and use thereof
WO2003054009A3 (de)	2003-11-06	Apoptotisch wirksame peptide
AU2002319236A1 (en)	2003-12-31	Method for the production of protamine